Humira vs Enbrel vs Cimzia During Pregnancy

How do the options compare?

The lens is a clinician's: guideline endorsement, pregnancy evidence, dosing, onset, and tolerability. Cost and formulation notes appear where relevant.

• MotherToBaby reports that studies of nearly 700 adalimumab-exposed pregnancies did not show a higher chance of birth defects, while disease-related factors can complicate interpretation of other findings. 1
• MotherToBaby reports that most etanercept studies do not show a higher chance of birth defects, while some studies cannot separate medication effects from the underlying disease. 2
• MotherToBaby describes little to no placental transfer of certolizumab in measured cord and infant blood samples and reports no higher birth-defect rate in published exposure data. 3
• A study of 31 pregnancies with inflammatory bowel disease compared infliximab, adalimumab, and certolizumab. Certolizumab had much lower placental transfer than the two antibodies. Etanercept was not included, so this was not a direct comparison of all three options on this page. 4
• A cord-blood study included certolizumab, etanercept, adalimumab, and infliximab after different medication-stopping schedules. Etanercept was undetectable in its 30 samples; certolizumab was detectable in 5.9% of 68 samples. Different timing limits direct drug rankings. 5

Which option makes sense?

The comparison above is intentionally evidence-first, not brand-first. Please consult your healthcare provider to translate it into a plan that fits your pregnancy specifics.

Disclosure: Pregnancy Smart makes pregnancy supplements, though not in this category. This comparison is a plain description of the pregnancy evidence, not a sales page.